SNY
HealthcareSanofi · Drug Manufacturers - General · $105B
What is Sanofi?
Sanofi is a global pharmaceutical company headquartered in Paris, France, operating across pharmaceuticals, vaccines, and consumer healthcare. It serves patients in the United States, Europe, and markets worldwide.
Sanofi researches, develops, manufactures, and markets medicines, vaccines, and consumer health products. Revenue comes from specialty care drugs, established prescription medicines, pediatric and adult vaccines, and over-the-counter consumer brands covering areas such as allergy, pain, and digestive health.
The company was established in its current form in 2002 and is headquartered in Paris, France.
- Specialty care and immunology medicines
- Pediatric and adult vaccines
- Consumer healthcare and OTC products
- Rare disease and oncology therapies
Is SNY a Good Stock to Buy?
UQS Score rates SNY as Good overall, reflecting a balanced profile across its five pillars.
Sanofi's Quality and Risk pillars both register as Good, suggesting the business generates reliable results while maintaining a manageable risk profile. The Valuation pillar is rated Attractive, meaning the stock appears reasonably priced relative to its fundamentals.
Growth is rated Weak, indicating limited near-term expansion momentum, and the Moat pillar sits at Neutral, reflecting competitive pressure across several product categories.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SNY pay dividends?
Yes — Sanofi pays a dividend.
Sanofi pays a regular dividend, consistent with its profile as a large, established pharmaceutical company. The dividend reflects the company's ability to generate steady cash flows from its diversified product portfolio and its commitment to returning capital to shareholders.
When does SNY report earnings?
Sanofi reports earnings on a quarterly cadence, typical for large-cap equities listed on major exchanges.
Results across recent periods have reflected the company's diversified revenue base spanning pharmaceuticals, vaccines, and consumer health. Performance in specialty care has been a key area of focus, while the consumer healthcare segment provides a degree of stability.
For the most recent quarter's results, visit Sanofi's official investor relations page.
SNY Price History
+4.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Sanofi?
Based on Sanofi's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Sanofi do?
Sanofi is a multinational pharmaceutical company that researches, develops, and sells medicines, vaccines, and consumer health products. Its portfolio spans specialty care, rare diseases, immunology, oncology, and established prescription drugs, alongside a broad vaccines business and over-the-counter consumer brands.
Does SNY pay dividends?
Yes, Sanofi pays a regular dividend. As a large, mature pharmaceutical company, it has a history of returning capital to shareholders through consistent dividend payments. For current yield and payment details, check Sanofi's investor relations page or your brokerage.
When does SNY report earnings?
Sanofi reports on a quarterly cadence, in line with standard practice for large-cap companies. Exact dates are not available through our data source — visit Sanofi's investor relations page for the current earnings calendar.
Is SNY a good stock to buy?
UQS Score rates SNY as Good overall. The Valuation pillar is Attractive and both Quality and Risk are rated Good, which may appeal to investors seeking stability. However, the Weak Growth and Neutral Moat ratings are worth considering. The full pillar breakdown is available to Pro members.
Is SNY overvalued?
Based on the UQS Valuation pillar, SNY is rated Attractive, suggesting the stock is not considered overpriced relative to its fundamentals at the time of scoring. Valuation can shift with market conditions, so reviewing the full analysis is recommended.
What is SNY's market cap bracket?
Sanofi is classified as a large-cap company, reflecting its scale as one of the world's leading pharmaceutical groups with a significant global commercial footprint.
Who founded Sanofi?
Sanofi in its current form was established in 2002 through a series of mergers involving major European pharmaceutical companies. Its origins trace back to earlier French and German pharmaceutical groups. Full historical context is widely available through public sources.
Is SNY a long-term quality stock?
As a long-term quality indicator, SNY's Good UQS Score — supported by Good Quality and Risk ratings and an Attractive Valuation — suggests a degree of fundamental stability. The Weak Growth pillar is a factor long-term investors should weigh. Pro members can access the complete analysis.
Unlock Full SNY Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores for SNY
- ✓Access detailed financial metrics and trend data
- ✓Compare SNY against sector peers on every pillar
- ✓Get the complete analyst-style quality breakdown in one place
Pro Analysis
SNY — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Jul 26, 2026 | 60.7 | 64.2 | 50.0 | 49.2 | 58.1 | 90.7 | 0.0 |
| Jul 25, 2026 | 60.7 | 64.2 | 50.0 | 49.2 | 58.1 | 90.3 | +0.1 |
| Jul 24, 2026 | 60.6 | 64.2 | 50.0 | 49.2 | 58.1 | 90.1 | 0.0 |
| Jul 23, 2026 | 60.6 | 64.2 | 50.0 | 49.2 | 58.1 | 90.2 | -0.1 |
| Jul 22, 2026 | 60.7 | 64.2 | 50.0 | 49.2 | 58.1 | 90.3 | +0.1 |
| Jul 21, 2026 | 60.6 | 64.2 | 50.0 | 49.2 | 58.1 | 89.8 | +0.1 |
| Jul 20, 2026 | 60.5 | 64.2 | 50.0 | 49.2 | 58.1 | 89.2 | 0.0 |
| Jul 18, 2026 | 60.5 | 64.2 | 50.0 | 49.2 | 58.1 | 89.1 | 0.0 |
| Jul 17, 2026 | 60.5 | 64.2 | 50.0 | 49.2 | 58.1 | 89.4 | +0.3 |
| Jul 16, 2026 | 60.2 | 64.2 | 50.0 | 49.2 | 58.1 | 87.5 | -0.4 |
SNY — Pillar Breakdown
Quality
— 64.2/100 (25%)Sanofi shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 49.2/100 (20%)Sanofi shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 58.1/100 (15%)Sanofi maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 87.5/100 (15%)Sanofi appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 50/100 (25%)Sanofi possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SNY.
Score Composition
Financial Data
More Stock Analysis
How is the SNY UQS Score Calculated?
The UQS (Unified Quality Score) for Sanofi is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Sanofi's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Sanofi is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.